SciSparc announced that as part of its ongoing collaboration with Clearmind Medicine, an international patent application under the Patent Cooperation Treaty has been published for the innovative combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines. As part of their collaboration, SciSparc and Clearmind are researching innovative combination therapies that combine psychedelic molecules with the N-Acylethanolamines family, including Palmitoylethanolamide. To date, thirteen patents related to this collaboration have been filed by Clearmind with the U.S. Patent and Trademark Office, as well as in several other global jurisdictions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRC:
- SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
- SciSparc and Clearmind Innovate in Mental Health Therapy
- SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
- SciSparc, Clearmind Medicine deal leads to publication of ketamine combo
- SciSparc files to sell 21M ordinary shares for holders